董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Zaki Rakib | 男 | President, Chairman and Director | 67 | 116.29万美元 | 未持股 | 2026-05-12 |
| David Ryan | 男 | Vice-President, Investor Relations, Secretary and Director | 60 | 4.45万美元 | 3.90 | 2026-05-12 |
| Vivien Rakib | 女 | Director | 67 | 2.66万美元 | 304.17 | 2026-05-12 |
| John Fiddick | 男 | Director | 85 | 2.66万美元 | 未持股 | 2026-05-12 |
| Anne Binder | 女 | Director | 75 | 未披露 | 1.77 | 2026-05-12 |
| Hezi Levy | 男 | Director | -- | 未披露 | 未持股 | 2026-05-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ilana Belzer | 女 | Chief Operating Officer | 66 | 22.59万美元 | 0.05 | 2026-05-12 |
| Alan Rootenberg | 男 | Chief Financial Officer | 74 | 3.15万美元 | 未持股 | 2026-05-12 |
| Ilan Sobel | 男 | Chief Executive Officer | 52 | 48.16万美元 | 21.69 | 2026-05-12 |
| Zaki Rakib | 男 | President, Chairman and Director | 67 | 116.29万美元 | 未持股 | 2026-05-12 |
| Yoheved Hagay | 女 | Chief Technology Officer | 68 | 37.75万美元 | 3.17 | 2026-05-12 |
| Brian Cornblatt | 男 | Chief Medical Officer | 52 | 43.01万美元 | 未持股 | 2026-05-12 |
| David Ryan | 男 | Vice-President, Investor Relations, Secretary and Director | 60 | 4.45万美元 | 3.90 | 2026-05-12 |
| Nedira Salzman Frenkel | 女 | Vice President of Business Development | -- | 未披露 | 未持股 | 2026-05-12 |
董事简历
中英对照 | 中文 | 英文- Zaki Rakib
-
Zaki Rakib，自2020年6月起担任公司总裁、董事长、董事，此前于2018年9月至2020年6月担任公司首席执行官。他自2018年9月起担任BioHarvest Israel的首席执行官和董事，自2018年2月起担任BioHarvest Delaware的董事，并于2014年7月至2021年12月担任Dolarin的董事。Rakib博士在软件、电信硬件、半导体、细胞操作和生物科学领域拥有丰富的经验，曾领导开发多项前沿创新。凭借他在技术科学方面的基础，Rakib博士是在他共同创立的公司Terayon Communication Systems发明了第一个电缆调制解调器和S-CDMA技术之后，电信行业的首批领导者之一。Rakib博士拥有以色列本-古里安大学的理学学士（1978年）、理学硕士（1981年）和工程学博士（1984年）。
Zaki Rakib,has served as the President, Chairman and director of the Company since June 2020, previously serving as the Chief Executive Officer of the Company from September 2018 to June 2020. He has served as the Chief Executive Officer and a director of BioHarvest Israel since September 2018, a director of BioHarvest Delaware since February 2018 and a director of Dolarin from July 2014 to December 2021. Dr. Rakib has experience within the software, telecommunications hardware, semiconductors, cellular operations and bioscience categories, where he has led the development of multiple cutting-edge innovations. Leveraging his foundation in technical sciences, Dr. Rakib was one of the first leaders in the telecommunications industry after the company he co-founded, Terayon Communication Systems, invented the first cable modem and S-CDMA technology. Dr. Rakib holds a Bachelor of Science (1978), Master of Science (1981) and a Ph.D. in Engineering (1984) from Ben-Gurion University in Israel. - Zaki Rakib，自2020年6月起担任公司总裁、董事长、董事，此前于2018年9月至2020年6月担任公司首席执行官。他自2018年9月起担任BioHarvest Israel的首席执行官和董事，自2018年2月起担任BioHarvest Delaware的董事，并于2014年7月至2021年12月担任Dolarin的董事。Rakib博士在软件、电信硬件、半导体、细胞操作和生物科学领域拥有丰富的经验，曾领导开发多项前沿创新。凭借他在技术科学方面的基础，Rakib博士是在他共同创立的公司Terayon Communication Systems发明了第一个电缆调制解调器和S-CDMA技术之后，电信行业的首批领导者之一。Rakib博士拥有以色列本-古里安大学的理学学士（1978年）、理学硕士（1981年）和工程学博士（1984年）。
- Zaki Rakib,has served as the President, Chairman and director of the Company since June 2020, previously serving as the Chief Executive Officer of the Company from September 2018 to June 2020. He has served as the Chief Executive Officer and a director of BioHarvest Israel since September 2018, a director of BioHarvest Delaware since February 2018 and a director of Dolarin from July 2014 to December 2021. Dr. Rakib has experience within the software, telecommunications hardware, semiconductors, cellular operations and bioscience categories, where he has led the development of multiple cutting-edge innovations. Leveraging his foundation in technical sciences, Dr. Rakib was one of the first leaders in the telecommunications industry after the company he co-founded, Terayon Communication Systems, invented the first cable modem and S-CDMA technology. Dr. Rakib holds a Bachelor of Science (1978), Master of Science (1981) and a Ph.D. in Engineering (1984) from Ben-Gurion University in Israel.
- David Ryan
-
David Ryan，拥有投资和公开市场方面的经验。在过去的20年里，他参与了将多个首次公开募股推向市场的工作。他曾在一级和二级融资中帮助为众多上市公司筹集股权和债务融资，他曾在上市公司董事会任职，担任过从总裁到董事的各种职务。Ryan先生为审计委员会成员，于2020年11月至2022年4月期间担任或曾经担任HydroGraph Clean Power Inc.（“HydroGraph”）董事；于2019年8月至2022年3月期间担任International Battery Metals Ltd.（“International Battery”）董事（曾于2018年8月至2019年4月期间担任International Battery董事）；于2017年3月至2020年5月期间担任GlobeX Data Ltd.董事；首席执行官自2017年1月起担任Scotch Creek Ventures Inc.（“Scotch Creek”）董事；自2017年10月至2023年10月担任Ovation Science Inc.（“Ovation”）董事；自2010年8月起担任InsuraGuest Technologies Inc.（“InsuraGuest”）董事；自2020年11月起担任Glenstar Ventures Corp.（“Glenstar”）首席执行官、总裁和董事，自2013年4月起担任公司秘书和董事，自2020年6月起担任公司投资者关系副总裁（此前曾于2013年4月至2020年6月担任公司总裁）。
David Ryan,has experience in investment and public markets. For the past 20 years, he has been part of bringing multiple initial public offerings to market. He has helped raise both equity and debt financings for numerous public companies in both primary and secondary financings, and he has served on the board of public companies and in various roles, from president to director. Mr. Ryan is a member of the Audit Committee and serves or has served as a director of HydroGraph Clean Power Inc. ("HydroGraph") from November 2020 to April 2022; a director of International Battery Metals Ltd. ("International Battery") from August 2019 to March 2022 (previously served as a director of International Battery from August 2018 to April 2019); a director of GlobeX Data Ltd. fromMarch 2017 to May 2020; the Chief Executive Officer and a director of Scotch Creek Ventures Inc. ("Scotch Creek") since January 2017; a director of Ovation Science Inc. ("Ovation") from October 2017 to October 2023; a director of InsuraGuest Technologies Inc. ("InsuraGuest") since August 2010; the Chief Executive Officer, President and a director of Glenstar Ventures Corp. ("Glenstar") since November 2020, and the Secretary and a director of the Company since April 2013 and Vice-President, Investor Relations, of the Company since June 2020 (previously served as the President of the Company from April 2013 to June 2020). - David Ryan，拥有投资和公开市场方面的经验。在过去的20年里，他参与了将多个首次公开募股推向市场的工作。他曾在一级和二级融资中帮助为众多上市公司筹集股权和债务融资，他曾在上市公司董事会任职，担任过从总裁到董事的各种职务。Ryan先生为审计委员会成员，于2020年11月至2022年4月期间担任或曾经担任HydroGraph Clean Power Inc.（“HydroGraph”）董事；于2019年8月至2022年3月期间担任International Battery Metals Ltd.（“International Battery”）董事（曾于2018年8月至2019年4月期间担任International Battery董事）；于2017年3月至2020年5月期间担任GlobeX Data Ltd.董事；首席执行官自2017年1月起担任Scotch Creek Ventures Inc.（“Scotch Creek”）董事；自2017年10月至2023年10月担任Ovation Science Inc.（“Ovation”）董事；自2010年8月起担任InsuraGuest Technologies Inc.（“InsuraGuest”）董事；自2020年11月起担任Glenstar Ventures Corp.（“Glenstar”）首席执行官、总裁和董事，自2013年4月起担任公司秘书和董事，自2020年6月起担任公司投资者关系副总裁（此前曾于2013年4月至2020年6月担任公司总裁）。
- David Ryan,has experience in investment and public markets. For the past 20 years, he has been part of bringing multiple initial public offerings to market. He has helped raise both equity and debt financings for numerous public companies in both primary and secondary financings, and he has served on the board of public companies and in various roles, from president to director. Mr. Ryan is a member of the Audit Committee and serves or has served as a director of HydroGraph Clean Power Inc. ("HydroGraph") from November 2020 to April 2022; a director of International Battery Metals Ltd. ("International Battery") from August 2019 to March 2022 (previously served as a director of International Battery from August 2018 to April 2019); a director of GlobeX Data Ltd. fromMarch 2017 to May 2020; the Chief Executive Officer and a director of Scotch Creek Ventures Inc. ("Scotch Creek") since January 2017; a director of Ovation Science Inc. ("Ovation") from October 2017 to October 2023; a director of InsuraGuest Technologies Inc. ("InsuraGuest") since August 2010; the Chief Executive Officer, President and a director of Glenstar Ventures Corp. ("Glenstar") since November 2020, and the Secretary and a director of the Company since April 2013 and Vice-President, Investor Relations, of the Company since June 2020 (previously served as the President of the Company from April 2013 to June 2020).
- Vivien Rakib
-
Vivien Rakib，自2007年起担任BioHarvest Israel董事，自2018年9月起担任公司董事。Rakib女士在硅谷从事软件开发工作十八年。她是一位活跃的科技初创投资者，并在多个非政府组织的董事会任职。她还自2011年起担任Shaker和CoPro的董事，自2013年起担任。Rakib女士拥有以色列本古里安大学的科学、数学和计算机科学学士学位（1984年）。
Vivien Rakib,has served as a director of BioHarvest Israel since 2007 and a director of the Company since September 2018. Ms. Rakib worked in software development in Silicon Valley for eighteen years. She is an active technology start-up investor and serves on the board of directors of several non-governmental organizations. She also serves as a director of each of Shaker since 2011 and CoPro since 2013. Ms. Rakib holds a Bachelor of Science, Mathematics and Computer Science (1984) from Ben Gurion University in Israel. - Vivien Rakib，自2007年起担任BioHarvest Israel董事，自2018年9月起担任公司董事。Rakib女士在硅谷从事软件开发工作十八年。她是一位活跃的科技初创投资者，并在多个非政府组织的董事会任职。她还自2011年起担任Shaker和CoPro的董事，自2013年起担任。Rakib女士拥有以色列本古里安大学的科学、数学和计算机科学学士学位（1984年）。
- Vivien Rakib,has served as a director of BioHarvest Israel since 2007 and a director of the Company since September 2018. Ms. Rakib worked in software development in Silicon Valley for eighteen years. She is an active technology start-up investor and serves on the board of directors of several non-governmental organizations. She also serves as a director of each of Shaker since 2011 and CoPro since 2013. Ms. Rakib holds a Bachelor of Science, Mathematics and Computer Science (1984) from Ben Gurion University in Israel.
- John Fiddick
-
John Fiddick，自2019年2月起担任公司董事，于1984年为蒙特利尔银行（“BMO”）创立了“上市公司银行集团”，在2017年8月退休之前，他是一个专门为上市公司提供服务的15人团队的一员。在效力于BMO的58年间，他获得了房地产牌照和经纪人牌照。Fiddick先生是审计委员会成员，此前曾于2019年6月至2020年9月担任Makara Mining Corp.的董事。
John Fiddick,a director of the Company since February 2019, founded the "Public Company Banking Group" for the Bank of Montreal ("BMO") in 1984 and was part of a 15-person team specializing in servicing public companies before retiring in August 2017. During his 58 years with BMO, he obtained his real estate license and broker's license. Mr. Fiddick is a member of the Audit Committee and previously served as a director of Makara Mining Corp. from June 2019 to September 2020. - John Fiddick，自2019年2月起担任公司董事，于1984年为蒙特利尔银行（“BMO”）创立了“上市公司银行集团”，在2017年8月退休之前，他是一个专门为上市公司提供服务的15人团队的一员。在效力于BMO的58年间，他获得了房地产牌照和经纪人牌照。Fiddick先生是审计委员会成员，此前曾于2019年6月至2020年9月担任Makara Mining Corp.的董事。
- John Fiddick,a director of the Company since February 2019, founded the "Public Company Banking Group" for the Bank of Montreal ("BMO") in 1984 and was part of a 15-person team specializing in servicing public companies before retiring in August 2017. During his 58 years with BMO, he obtained his real estate license and broker's license. Mr. Fiddick is a member of the Audit Committee and previously served as a director of Makara Mining Corp. from June 2019 to September 2020.
- Anne Binder
-
Anne Binder，专门从事中小企业的支持和融资。自1996年起，她主要在金融、电子、综合技术解决方案和奢侈品等多个领域运营的私营公司担任财务战略顾问和独立董事。此前，她曾担任Tikehau Investment Management SAS的高级顾问，这是一家专门从事企业债务融资的管理公司。Binder女士此前还曾担任Lectra、Oceasoft、CNCEF（Chambre Nationale des Conseils Experts Financiers）和CNCIF（Chambre Nationale des Conseillers en Investissements Financiers）的董事，以及N mes经济发展公司金融投资机构监事会成员。从1993年到1996年，Binder女士担任国际金融服务集团通用电气资本公司负责法国发展的董事以及该公司法国子公司的董事。从1990年到1993年，Binder女士是控股公司的董事总经理和EURIS投资基金的副董事总经理。从1983年到1990年，她参与创建了帕拉斯集团，她是该集团的董事。Binder女士于1978年至1982年担任银行和工业控股公司G é n é rale Occidentale的副总裁。Binder女士拥有法国Sciences Po的公共事务硕士学位（1971年）和法国INSEAD的MBA学位（1974年）。
Anne Binder,specializes in the support and financing of small and medium-sized enterprises. Since 1996, she has worked as a financial strategy consultant and independent director for mainly private companies operating in various sectors, such as finance, electronics, integrated technological solutions and luxury. She previously acted as a senior advisor to Tikehau Investment Management SAS, a management company specializing in corporate debt financing. Ms. Binder also previously served as a director of each of Lectra, Oceasoft, CNCEF (Chambre Nationale des Conseils Experts Financiers) and CNCIF (Chambre Nationale des Conseillers en Investissements Financiers) and as a member of the supervisory board of the Financial Investment Agency, Economic Development of Nmes. From 1993 to 1996, Ms. Binder was a director in charge of development in France for the international financial services group General Electric Capital, and director of its French subsidiary. From 1990 to 1993, Ms. Binder was the managing director of the holding company and deputy managing director of the EURIS investment fund. From 1983 to 1990, she participated in the creation of the Pallas Group of which she was a director. Ms. Binder was a Vice-President of Générale Occidentale, a bank and industrial holding company, from 1978 to 1982. Ms. Binder holds a Master in Public Affairs (1971) from Sciences Po in France and an MBA (1974) from INSEAD in France. - Anne Binder，专门从事中小企业的支持和融资。自1996年起，她主要在金融、电子、综合技术解决方案和奢侈品等多个领域运营的私营公司担任财务战略顾问和独立董事。此前，她曾担任Tikehau Investment Management SAS的高级顾问，这是一家专门从事企业债务融资的管理公司。Binder女士此前还曾担任Lectra、Oceasoft、CNCEF（Chambre Nationale des Conseils Experts Financiers）和CNCIF（Chambre Nationale des Conseillers en Investissements Financiers）的董事，以及N mes经济发展公司金融投资机构监事会成员。从1993年到1996年，Binder女士担任国际金融服务集团通用电气资本公司负责法国发展的董事以及该公司法国子公司的董事。从1990年到1993年，Binder女士是控股公司的董事总经理和EURIS投资基金的副董事总经理。从1983年到1990年，她参与创建了帕拉斯集团，她是该集团的董事。Binder女士于1978年至1982年担任银行和工业控股公司G é n é rale Occidentale的副总裁。Binder女士拥有法国Sciences Po的公共事务硕士学位（1971年）和法国INSEAD的MBA学位（1974年）。
- Anne Binder,specializes in the support and financing of small and medium-sized enterprises. Since 1996, she has worked as a financial strategy consultant and independent director for mainly private companies operating in various sectors, such as finance, electronics, integrated technological solutions and luxury. She previously acted as a senior advisor to Tikehau Investment Management SAS, a management company specializing in corporate debt financing. Ms. Binder also previously served as a director of each of Lectra, Oceasoft, CNCEF (Chambre Nationale des Conseils Experts Financiers) and CNCIF (Chambre Nationale des Conseillers en Investissements Financiers) and as a member of the supervisory board of the Financial Investment Agency, Economic Development of Nmes. From 1993 to 1996, Ms. Binder was a director in charge of development in France for the international financial services group General Electric Capital, and director of its French subsidiary. From 1990 to 1993, Ms. Binder was the managing director of the holding company and deputy managing director of the EURIS investment fund. From 1983 to 1990, she participated in the creation of the Pallas Group of which she was a director. Ms. Binder was a Vice-President of Générale Occidentale, a bank and industrial holding company, from 1978 to 1982. Ms. Binder holds a Master in Public Affairs (1971) from Sciences Po in France and an MBA (1974) from INSEAD in France.
- Hezi Levy
-
Hezi Levy，加入董事会时拥有数十年在以色列医疗保健系统的领导经验，被全球公认为世界上最先进的系统之一。利维教授是一名受过教育的医生，此前曾担任以色列卫生部总干事，包括在新冠肺炎大流行期间，在这一特殊挑战时期，他在指导国家医疗保健政策方面发挥了核心作用。利维还曾担任以色列国防军（IDF）医疗团团长，准将军衔，并曾多年担任巴尔齐莱医疗中心总经理，负责监督以色列的一家主要医院和复杂的医疗保健业务。
Hezi Levy,joins the Board with decades of leadership experience across Israel's healthcare system, recognized globally as one of the world's most advanced. A physician by education, Prof. Levy previously served as Director General of the Israeli Ministry of Health, including during the COVID-19 pandemic, where he played a central role in guiding national healthcare policy during a period of exceptional challenge.Prof. Levy also served as Head of the Medical Corps of the Israel Defense Forces (IDF) with the rank of Brigadier General and was the General Manager of Barzilai Medical Center for many years, overseeing one of Israel's major hospitals and complex healthcare operations. - Hezi Levy，加入董事会时拥有数十年在以色列医疗保健系统的领导经验，被全球公认为世界上最先进的系统之一。利维教授是一名受过教育的医生，此前曾担任以色列卫生部总干事，包括在新冠肺炎大流行期间，在这一特殊挑战时期，他在指导国家医疗保健政策方面发挥了核心作用。利维还曾担任以色列国防军（IDF）医疗团团长，准将军衔，并曾多年担任巴尔齐莱医疗中心总经理，负责监督以色列的一家主要医院和复杂的医疗保健业务。
- Hezi Levy,joins the Board with decades of leadership experience across Israel's healthcare system, recognized globally as one of the world's most advanced. A physician by education, Prof. Levy previously served as Director General of the Israeli Ministry of Health, including during the COVID-19 pandemic, where he played a central role in guiding national healthcare policy during a period of exceptional challenge.Prof. Levy also served as Head of the Medical Corps of the Israel Defense Forces (IDF) with the rank of Brigadier General and was the General Manager of Barzilai Medical Center for many years, overseeing one of Israel's major hospitals and complex healthcare operations.
高管简历
中英对照 | 中文 | 英文- Ilana Belzer
Ilana Belzer于2015年至2023年4月期间担任Collplant生物技术有限公司（“CollPlant”）的首席运营官，该公司是一家在纳斯达克上市的再生和美容医学公司，也是一家总部位于以色列的生物技术创新者。Belzer博士负责CollPlant的运营，包括两个生产设施、工艺和基础设施工程、供应链、维护以及分析和质量控制。在担任该职务期间，她领导并管理了烟叶生物质生产、提取和纯化的农业基础设施，以提供制药级胶原蛋白以及各种基于胶原蛋白的配方的放大和验证。Belzer博士实施了重大的工艺改进，取得了业务成果，包括将生产良率提高了270%以及升级了“洁净室”GMP设施以支持无菌生产。在运营和供应链端，她协调整个生产计划，精简上下游流程，构建运营预算和管控措施并负责所有客户订单的履行。在加入Collplant之前，Belzer博士于2012年至2015年在BioHarvest Israel担任首席运营官。她监督将植物合成平台技术转化为工业过程。在担任BioHarvest Israel的第一个职位之前，Belzer博士还曾于2004年至2008年担任Omrix Ltd.的工厂经理，负责运营（制造、供应链、工程、维护、包装和质量控制），并于2008年2月至2012年11月担任Procognia Ltd.的研发和运营副总裁，在那里她领导了由生物分析和解释软件组成的新型分析集成平台的开发。她还在癌症诊断和干细胞领域开发了新的应用。Belzer博士拥有以色列特拉维夫大学生命科学学院、微生物学和细胞生物学系的博士学位（1990年）、理学硕士学位（1986年）和理学学士学位（1983年）。
Ilana Belzer,served from 2015 until April 2023 as the Chief Operating Officer of CollPlant Biotechnologies Ltd. ("Collplant"), a NASDAQ-listed regenerative and aesthetics medicine company and biotech innovator based in Israel. Dr. Belzer was responsible for Collplant's operations, including two production facilities, process and infrastructure engineering, supply chain, maintenance, and analytical and quality control. In that capacity, she led and managed agriculture infrastructure for tobacco leaf biomass production, extraction and purification to deliver pharma-grade collagen and the scale up and validation of various collagen-based formulations. Dr. Belzer implemented significant process improvements, achieving business results, including an increase of 270% in production yield as well as the upgrade of the "clean rooms" GMP facility to support aseptic production. On the operation and supply chain sides, she coordinated the entire production plan, streamlined both upstream and downstream processes, built the operations budget and control measures and was responsible for the fulfillment of all customer orders. Prior to moving to CollPlant, Dr. Belzer served as the Chief Operating Officer at BioHarvest Israel from 2012 to 2015. She oversaw turning the Botanical Synthesis Platform Technology into an industrial process. Prior to her first role at BioHarvest Israel, Dr. Belzer was also Plant Manager at Omrix Ltd., from 2004 to 2008, where she was responsible for operations (manufacturing, supply chain, engineering, maintenance, packaging and quality control) and was Vice-President of Research and Development and Operations at Procognia Ltd., from February 2008 to November 2012, where she led the development of a novel analytical integrated platform composed of a biological assay and interpretation software. She also developed new applications in the field of cancer diagnostics and stem cells. Dr. Belzer holds a Ph.D. (1990), Master of Science (1986) and Bachelor of Science (1983) from the Tel Aviv University Faculty of Life Sciences, Microbiology and Cell Biology department in Israel.- Ilana Belzer于2015年至2023年4月期间担任Collplant生物技术有限公司（“CollPlant”）的首席运营官，该公司是一家在纳斯达克上市的再生和美容医学公司，也是一家总部位于以色列的生物技术创新者。Belzer博士负责CollPlant的运营，包括两个生产设施、工艺和基础设施工程、供应链、维护以及分析和质量控制。在担任该职务期间，她领导并管理了烟叶生物质生产、提取和纯化的农业基础设施，以提供制药级胶原蛋白以及各种基于胶原蛋白的配方的放大和验证。Belzer博士实施了重大的工艺改进，取得了业务成果，包括将生产良率提高了270%以及升级了“洁净室”GMP设施以支持无菌生产。在运营和供应链端，她协调整个生产计划，精简上下游流程，构建运营预算和管控措施并负责所有客户订单的履行。在加入Collplant之前，Belzer博士于2012年至2015年在BioHarvest Israel担任首席运营官。她监督将植物合成平台技术转化为工业过程。在担任BioHarvest Israel的第一个职位之前，Belzer博士还曾于2004年至2008年担任Omrix Ltd.的工厂经理，负责运营（制造、供应链、工程、维护、包装和质量控制），并于2008年2月至2012年11月担任Procognia Ltd.的研发和运营副总裁，在那里她领导了由生物分析和解释软件组成的新型分析集成平台的开发。她还在癌症诊断和干细胞领域开发了新的应用。Belzer博士拥有以色列特拉维夫大学生命科学学院、微生物学和细胞生物学系的博士学位（1990年）、理学硕士学位（1986年）和理学学士学位（1983年）。
- Ilana Belzer,served from 2015 until April 2023 as the Chief Operating Officer of CollPlant Biotechnologies Ltd. ("Collplant"), a NASDAQ-listed regenerative and aesthetics medicine company and biotech innovator based in Israel. Dr. Belzer was responsible for Collplant's operations, including two production facilities, process and infrastructure engineering, supply chain, maintenance, and analytical and quality control. In that capacity, she led and managed agriculture infrastructure for tobacco leaf biomass production, extraction and purification to deliver pharma-grade collagen and the scale up and validation of various collagen-based formulations. Dr. Belzer implemented significant process improvements, achieving business results, including an increase of 270% in production yield as well as the upgrade of the "clean rooms" GMP facility to support aseptic production. On the operation and supply chain sides, she coordinated the entire production plan, streamlined both upstream and downstream processes, built the operations budget and control measures and was responsible for the fulfillment of all customer orders. Prior to moving to CollPlant, Dr. Belzer served as the Chief Operating Officer at BioHarvest Israel from 2012 to 2015. She oversaw turning the Botanical Synthesis Platform Technology into an industrial process. Prior to her first role at BioHarvest Israel, Dr. Belzer was also Plant Manager at Omrix Ltd., from 2004 to 2008, where she was responsible for operations (manufacturing, supply chain, engineering, maintenance, packaging and quality control) and was Vice-President of Research and Development and Operations at Procognia Ltd., from February 2008 to November 2012, where she led the development of a novel analytical integrated platform composed of a biological assay and interpretation software. She also developed new applications in the field of cancer diagnostics and stem cells. Dr. Belzer holds a Ph.D. (1990), Master of Science (1986) and Bachelor of Science (1983) from the Tel Aviv University Faculty of Life Sciences, Microbiology and Cell Biology department in Israel.
- Alan Rootenberg
Alan Rootenberg自2022年6月14日起担任Clearmind医药公司Chief Financial Officer，自2020年4月15日起担任Clearmind医药公司董事。Rootenberg先生自2021年8月起担任Alpha Gold North Inc.的Chief Financial Officer。此外，Rootenberg先生自2018年11月起担任BioHarvest Sciences，Inc. CSE：BHSC的Chief Financial Officer，并自2011年11月起担任Eco（Atlantic）Oil & Gas Ltd.（TSXV：EOG）的Chief Financial Officer。这些公司包括矿产勘探、采矿、技术、营养产品和大麻行业的公司。他还担任过多家上市公司的董事，这些公司包括A2Z Smart Technologies Corp.（AZ）和Solvbl Solutions Inc.（CSE：SOLV）。Rootenberg先生在南非约翰内斯堡的威特沃特斯兰德大学获得商学学士学位，并在加拿大安大略省获得注册会计师资格。
Alan Rootenberg has served as Chief Financial Officer since June 14, 2022. Mr. Rootenberg also served as Director from April 15, 2020 until December 2022. Mr. Rootenberg has served as the Chief Financial Officer of Alpha Gold North Inc. since August 2021. In addition, Mr. Rootenberg has served as the Chief Financial Officer of BioHarvest Sciences, Inc. (CSE: BHSC) since November 2018 and has served as the Chief Financial Officer of Eco (Atlantic) Oil & Gas Ltd. (TSXV: EOG) since November 2011 and a public company, Anteros Metals Inc. These companies include mineral exploration, mining, technology and nutraceutical products. He also serves as a director of a publicly traded company, A2Z Smart Technologies Corp. (TSXV: AZ). Mr. Rootenberg has a Bachelor of Commerce degree from the University of the Witwatersrand in Johannesburg, South Africa and received his CPA designation in Ontario, Canada.- Alan Rootenberg自2022年6月14日起担任Clearmind医药公司Chief Financial Officer，自2020年4月15日起担任Clearmind医药公司董事。Rootenberg先生自2021年8月起担任Alpha Gold North Inc.的Chief Financial Officer。此外，Rootenberg先生自2018年11月起担任BioHarvest Sciences，Inc. CSE：BHSC的Chief Financial Officer，并自2011年11月起担任Eco（Atlantic）Oil & Gas Ltd.（TSXV：EOG）的Chief Financial Officer。这些公司包括矿产勘探、采矿、技术、营养产品和大麻行业的公司。他还担任过多家上市公司的董事，这些公司包括A2Z Smart Technologies Corp.（AZ）和Solvbl Solutions Inc.（CSE：SOLV）。Rootenberg先生在南非约翰内斯堡的威特沃特斯兰德大学获得商学学士学位，并在加拿大安大略省获得注册会计师资格。
- Alan Rootenberg has served as Chief Financial Officer since June 14, 2022. Mr. Rootenberg also served as Director from April 15, 2020 until December 2022. Mr. Rootenberg has served as the Chief Financial Officer of Alpha Gold North Inc. since August 2021. In addition, Mr. Rootenberg has served as the Chief Financial Officer of BioHarvest Sciences, Inc. (CSE: BHSC) since November 2018 and has served as the Chief Financial Officer of Eco (Atlantic) Oil & Gas Ltd. (TSXV: EOG) since November 2011 and a public company, Anteros Metals Inc. These companies include mineral exploration, mining, technology and nutraceutical products. He also serves as a director of a publicly traded company, A2Z Smart Technologies Corp. (TSXV: AZ). Mr. Rootenberg has a Bachelor of Commerce degree from the University of the Witwatersrand in Johannesburg, South Africa and received his CPA designation in Ontario, Canada.
- Ilan Sobel
Ilan Sobel，自2020年7月起担任公司首席执行官。他带来了公司的第一款产品VINIA，到北美，建造一台直接面向消费者的机器，现在正在创造收入。维尼亚的上市经验为公司近期的营养保健品植物细胞库产品管线建立了模板。除了商业重点和规划，他将生产能力从研发提升到工业水平，并建立了一家生物技术公司，拥有新颖的、甚至是可申请专利的、以科学为基础、以临床试验为后盾的植物为基础的产品。在加入公司之前，Sobel先生曾于2014年11月至2020年6月担任Weissbeerger的首席运营官和首席商务官。以这种身份，他在建立一个颠覆性的大数据、物联网和软件公司方面发挥了领导作用，为主要的饮料公司提供服务，这些公司最终被百威英博收购。在此之前，Sobel先生于1997年至2014年在可口可乐公司工作，担任关键的高级领导职务，在不同的全球市场（包括美国、中国大陆、香港、台湾、泰国、新加坡、马来西亚、越南、菲律宾和南非）创造收入和利润增长，并改善品牌健康趋势。Sobel先生拥有澳大利亚新南威尔士大学市场营销和人力资源管理学士学位（1997年）。
Ilan Sobel,has served as the Chief Execuive Officer of the Company since July 2020. He brought the Company's first product, VINIA, to North America, building a direct-to-consumer machine that is now generating revenue. VINIA's go-to-market experience has established a template for the Company's near-term product pipeline of nutraceutical plant cell banks. In addition to commercial focus and planning, he scaled production capabilities from research and development up to industrial levels and built a biotechnology company with novel, and even patentable, plant-based products that are based on science and backed by clinical trials. Prior to the Company, Mr. Sobel served as the Chief Operating Officer and then Chief Commercial Officer, from November 2014 to June 2020, of Weissbeerger. In this capacity, he played a leadership role in building a disruptive big data, internet of things and software Company servicing major beverage players, which was ultimately purchased by Anheuser Busch InBev. Previously, Mr. Sobel worked at the Coca-Cola Company from 1997 to 2014, where he held key senior leadership positions generating revenue and profit growth and improving brand health trends across diverse global markets, including the United States, China, Hong Kong, Taiwan, Thailand, Singapore, Malaysia, Vietnam, the Philippines and South Africa. Mr. Sobel holds a Bachelor in Marketing and Human Resources Management (1997) from the University of New South Wales in Australia.- Ilan Sobel，自2020年7月起担任公司首席执行官。他带来了公司的第一款产品VINIA，到北美，建造一台直接面向消费者的机器，现在正在创造收入。维尼亚的上市经验为公司近期的营养保健品植物细胞库产品管线建立了模板。除了商业重点和规划，他将生产能力从研发提升到工业水平，并建立了一家生物技术公司，拥有新颖的、甚至是可申请专利的、以科学为基础、以临床试验为后盾的植物为基础的产品。在加入公司之前，Sobel先生曾于2014年11月至2020年6月担任Weissbeerger的首席运营官和首席商务官。以这种身份，他在建立一个颠覆性的大数据、物联网和软件公司方面发挥了领导作用，为主要的饮料公司提供服务，这些公司最终被百威英博收购。在此之前，Sobel先生于1997年至2014年在可口可乐公司工作，担任关键的高级领导职务，在不同的全球市场（包括美国、中国大陆、香港、台湾、泰国、新加坡、马来西亚、越南、菲律宾和南非）创造收入和利润增长，并改善品牌健康趋势。Sobel先生拥有澳大利亚新南威尔士大学市场营销和人力资源管理学士学位（1997年）。
- Ilan Sobel,has served as the Chief Execuive Officer of the Company since July 2020. He brought the Company's first product, VINIA, to North America, building a direct-to-consumer machine that is now generating revenue. VINIA's go-to-market experience has established a template for the Company's near-term product pipeline of nutraceutical plant cell banks. In addition to commercial focus and planning, he scaled production capabilities from research and development up to industrial levels and built a biotechnology company with novel, and even patentable, plant-based products that are based on science and backed by clinical trials. Prior to the Company, Mr. Sobel served as the Chief Operating Officer and then Chief Commercial Officer, from November 2014 to June 2020, of Weissbeerger. In this capacity, he played a leadership role in building a disruptive big data, internet of things and software Company servicing major beverage players, which was ultimately purchased by Anheuser Busch InBev. Previously, Mr. Sobel worked at the Coca-Cola Company from 1997 to 2014, where he held key senior leadership positions generating revenue and profit growth and improving brand health trends across diverse global markets, including the United States, China, Hong Kong, Taiwan, Thailand, Singapore, Malaysia, Vietnam, the Philippines and South Africa. Mr. Sobel holds a Bachelor in Marketing and Human Resources Management (1997) from the University of New South Wales in Australia.
- Zaki Rakib
Zaki Rakib，自2020年6月起担任公司总裁、董事长、董事，此前于2018年9月至2020年6月担任公司首席执行官。他自2018年9月起担任BioHarvest Israel的首席执行官和董事，自2018年2月起担任BioHarvest Delaware的董事，并于2014年7月至2021年12月担任Dolarin的董事。Rakib博士在软件、电信硬件、半导体、细胞操作和生物科学领域拥有丰富的经验，曾领导开发多项前沿创新。凭借他在技术科学方面的基础，Rakib博士是在他共同创立的公司Terayon Communication Systems发明了第一个电缆调制解调器和S-CDMA技术之后，电信行业的首批领导者之一。Rakib博士拥有以色列本-古里安大学的理学学士（1978年）、理学硕士（1981年）和工程学博士（1984年）。
Zaki Rakib,has served as the President, Chairman and director of the Company since June 2020, previously serving as the Chief Executive Officer of the Company from September 2018 to June 2020. He has served as the Chief Executive Officer and a director of BioHarvest Israel since September 2018, a director of BioHarvest Delaware since February 2018 and a director of Dolarin from July 2014 to December 2021. Dr. Rakib has experience within the software, telecommunications hardware, semiconductors, cellular operations and bioscience categories, where he has led the development of multiple cutting-edge innovations. Leveraging his foundation in technical sciences, Dr. Rakib was one of the first leaders in the telecommunications industry after the company he co-founded, Terayon Communication Systems, invented the first cable modem and S-CDMA technology. Dr. Rakib holds a Bachelor of Science (1978), Master of Science (1981) and a Ph.D. in Engineering (1984) from Ben-Gurion University in Israel.- Zaki Rakib，自2020年6月起担任公司总裁、董事长、董事，此前于2018年9月至2020年6月担任公司首席执行官。他自2018年9月起担任BioHarvest Israel的首席执行官和董事，自2018年2月起担任BioHarvest Delaware的董事，并于2014年7月至2021年12月担任Dolarin的董事。Rakib博士在软件、电信硬件、半导体、细胞操作和生物科学领域拥有丰富的经验，曾领导开发多项前沿创新。凭借他在技术科学方面的基础，Rakib博士是在他共同创立的公司Terayon Communication Systems发明了第一个电缆调制解调器和S-CDMA技术之后，电信行业的首批领导者之一。Rakib博士拥有以色列本-古里安大学的理学学士（1978年）、理学硕士（1981年）和工程学博士（1984年）。
- Zaki Rakib,has served as the President, Chairman and director of the Company since June 2020, previously serving as the Chief Executive Officer of the Company from September 2018 to June 2020. He has served as the Chief Executive Officer and a director of BioHarvest Israel since September 2018, a director of BioHarvest Delaware since February 2018 and a director of Dolarin from July 2014 to December 2021. Dr. Rakib has experience within the software, telecommunications hardware, semiconductors, cellular operations and bioscience categories, where he has led the development of multiple cutting-edge innovations. Leveraging his foundation in technical sciences, Dr. Rakib was one of the first leaders in the telecommunications industry after the company he co-founded, Terayon Communication Systems, invented the first cable modem and S-CDMA technology. Dr. Rakib holds a Bachelor of Science (1978), Master of Science (1981) and a Ph.D. in Engineering (1984) from Ben-Gurion University in Israel.
- Yoheved Hagay
Yoheved Hagay，自2018年9月起担任该公司的首席技术官，自2018年9月起担任BioHarvest Israel的首席技术官，此前曾于2008年1月至2018年8月担任BioHarvest Israel的首席执行官。她负责科技、知识产权和专利、法规事务、战略建设和实施，拥有医药和生物技术行业领先研发经验。在2005年共同创立BioHarvest Israel之前，Hagay博士曾担任Bio-Technology General的管理合伙人。那段时间，她评估了一大批科研项目和生物科技公司。Hagay博士曾在Bio-Technology General的多个职位任职15年，直到被Savient收购。在2002年至2005年她在Savient的最后一个职位上，她负责监督该公司的临床研究。Hagay博士拥有以色列希伯来大学生物技术博士学位（2004年）。
Yoheved Hagay,has been the Chief Technology Officer of each of the Company since September 2018 and BioHarvest Israel since September 2018, having previously served as the Chief Executive Officer of BioHarvest Israel from January 2008 to August 2018. She is responsible for science and technology, intellectual property and patents, regulatory affairs, strategy building and implementation, and she has experience in leading research and development in the pharmaceutical and biotechnology industry. Prior to co-founding BioHarvest Israel in 2005, Dr. Hagay served as the Managing Partner at Bio-Technology General. During that time, she evaluated a large number of scientific research projects and biotechnology companies. Dr. Hagay served in various positions in Bio-Technology General for 15 years, until it was acquired by Savient. In her last role at Savient from 2002 to 2005, she supervised that company's clinical studies. Dr. Hagay holds a Ph.D. in Biotechnology (2004) from Hebrew University in Israel.- Yoheved Hagay，自2018年9月起担任该公司的首席技术官，自2018年9月起担任BioHarvest Israel的首席技术官，此前曾于2008年1月至2018年8月担任BioHarvest Israel的首席执行官。她负责科技、知识产权和专利、法规事务、战略建设和实施，拥有医药和生物技术行业领先研发经验。在2005年共同创立BioHarvest Israel之前，Hagay博士曾担任Bio-Technology General的管理合伙人。那段时间，她评估了一大批科研项目和生物科技公司。Hagay博士曾在Bio-Technology General的多个职位任职15年，直到被Savient收购。在2002年至2005年她在Savient的最后一个职位上，她负责监督该公司的临床研究。Hagay博士拥有以色列希伯来大学生物技术博士学位（2004年）。
- Yoheved Hagay,has been the Chief Technology Officer of each of the Company since September 2018 and BioHarvest Israel since September 2018, having previously served as the Chief Executive Officer of BioHarvest Israel from January 2008 to August 2018. She is responsible for science and technology, intellectual property and patents, regulatory affairs, strategy building and implementation, and she has experience in leading research and development in the pharmaceutical and biotechnology industry. Prior to co-founding BioHarvest Israel in 2005, Dr. Hagay served as the Managing Partner at Bio-Technology General. During that time, she evaluated a large number of scientific research projects and biotechnology companies. Dr. Hagay served in various positions in Bio-Technology General for 15 years, until it was acquired by Savient. In her last role at Savient from 2002 to 2005, she supervised that company's clinical studies. Dr. Hagay holds a Ph.D. in Biotechnology (2004) from Hebrew University in Israel.
- Brian Cornblatt
Brian Cornblatt，自2022年5月起担任公司首席医疗官，Cornblatt博士负责开发和开展转化科学研究，以支持公司产品，包括人体临床试验。他还与包括公司顾问委员会成员在内的关键战略成员合作，作为科学顾问，他与约翰霍普金斯结直肠癌卓越中心、IntellxxDNA、International Nutrition Associates和Integration Health Solutions合作。Cornblatt博士自2010年起担任Nutramax Laboratories Consumer Care，Inc.（“Nutramax”）的消费者临床研究和科学总监和医疗总监。在担任这一职务时，Cornblatt博士开发了新颖的营养保健品配方，设计了支持产品的体外和临床研究，并为医疗保健工作者和消费者总结了支持实验室和临床研究。他最近的开发是一系列新产品（以及18项相关临床试验），这些产品提供了支持生产萝卜硫素所需的必要成分，萝卜硫素是一种具有许多新出现的适应症的植物化学物质。Cornblatt博士还是三（3）项已授权专利和四（4）项待批临时专利的发明人，这些专利专注于植物性生物活性化合物和健康促进。在加入Nutramax之前，Cornblatt博士曾于2007年至2009年担任天主教健康倡议（“CHI”）转化研究中心（“CTR”）的科学主任和开发者，该中心是一个联合分子研究实验室、国家生物储存库和诊断实验室。CTR支持了CHI四十（40）个肿瘤中心的研究计划。Cornblatt博士毕业于约翰霍普金斯大学医学院，获得药理学和分子科学博士学位（2004年），美国约翰霍普金斯大学彭博公共卫生学院环境Health Sciences毒理学分部博士后奖学金（2004年至2006年）。
Brian Cornblatt,As the Company's Chief Medical Officer since May 2022, Dr. Cornblatt is responsible for developing and carrying out translational scientific studies in support of the Company products, including human clinical trials. He also works with key strategy members, including members of the Company's advisory boards, and as a scientific consultant, he works with The Johns Hopkins Colorectal Cancer Center of Excellence, IntellxxDNA, International Nutrition Associates and Integration Health Solutions. Dr. Cornblatt has served as Director of Consumer Clinical Research and Science and as Medical Director at Nutramax Laboratories Consumer Care, Inc. ("Nutramax") since 2010. In this role, Dr. Cornblatt developed novel nutraceutical formulations, designed both in vitro and clinical studies in support of products, and summarized both supporting laboratory and clinical research for healthcare workers and consumers. His most recent development has been a novel line of products (and 18 related clinical trials) which deliver the essential ingredients needed to support the production of sulforaphane, a phytochemical with many emerging indications. Dr. Cornblatt is also the inventor of three (3) issued patents and four (4) pending provisional patents focused on plant-based bioactive compounds and health promotion. Prior to moving to Nutramax, Dr. Cornblatt was the Scientific Director and Developer of the Catholic Health Initiatives' ("CHI") Center for Translational Research ("CTR"), a combined molecular research laboratory, national biorepository and diagnostics laboratory, from 2007 to 2009. The CTR supported research initiatives throughout CHI's forty (40) Oncology centers. Dr. Cornblatt is a Johns Hopkins University School of Medicine graduate with a Ph.D. in Pharmacology and Molecular Sciences (2004) and a postdoctoral fellowship (2004 to 2006) from the Johns Hopkins Bloomberg School of Public Health, Environmental Health Sciences Division of Toxicology in the United States.- Brian Cornblatt，自2022年5月起担任公司首席医疗官，Cornblatt博士负责开发和开展转化科学研究，以支持公司产品，包括人体临床试验。他还与包括公司顾问委员会成员在内的关键战略成员合作，作为科学顾问，他与约翰霍普金斯结直肠癌卓越中心、IntellxxDNA、International Nutrition Associates和Integration Health Solutions合作。Cornblatt博士自2010年起担任Nutramax Laboratories Consumer Care，Inc.（“Nutramax”）的消费者临床研究和科学总监和医疗总监。在担任这一职务时，Cornblatt博士开发了新颖的营养保健品配方，设计了支持产品的体外和临床研究，并为医疗保健工作者和消费者总结了支持实验室和临床研究。他最近的开发是一系列新产品（以及18项相关临床试验），这些产品提供了支持生产萝卜硫素所需的必要成分，萝卜硫素是一种具有许多新出现的适应症的植物化学物质。Cornblatt博士还是三（3）项已授权专利和四（4）项待批临时专利的发明人，这些专利专注于植物性生物活性化合物和健康促进。在加入Nutramax之前，Cornblatt博士曾于2007年至2009年担任天主教健康倡议（“CHI”）转化研究中心（“CTR”）的科学主任和开发者，该中心是一个联合分子研究实验室、国家生物储存库和诊断实验室。CTR支持了CHI四十（40）个肿瘤中心的研究计划。Cornblatt博士毕业于约翰霍普金斯大学医学院，获得药理学和分子科学博士学位（2004年），美国约翰霍普金斯大学彭博公共卫生学院环境Health Sciences毒理学分部博士后奖学金（2004年至2006年）。
- Brian Cornblatt,As the Company's Chief Medical Officer since May 2022, Dr. Cornblatt is responsible for developing and carrying out translational scientific studies in support of the Company products, including human clinical trials. He also works with key strategy members, including members of the Company's advisory boards, and as a scientific consultant, he works with The Johns Hopkins Colorectal Cancer Center of Excellence, IntellxxDNA, International Nutrition Associates and Integration Health Solutions. Dr. Cornblatt has served as Director of Consumer Clinical Research and Science and as Medical Director at Nutramax Laboratories Consumer Care, Inc. ("Nutramax") since 2010. In this role, Dr. Cornblatt developed novel nutraceutical formulations, designed both in vitro and clinical studies in support of products, and summarized both supporting laboratory and clinical research for healthcare workers and consumers. His most recent development has been a novel line of products (and 18 related clinical trials) which deliver the essential ingredients needed to support the production of sulforaphane, a phytochemical with many emerging indications. Dr. Cornblatt is also the inventor of three (3) issued patents and four (4) pending provisional patents focused on plant-based bioactive compounds and health promotion. Prior to moving to Nutramax, Dr. Cornblatt was the Scientific Director and Developer of the Catholic Health Initiatives' ("CHI") Center for Translational Research ("CTR"), a combined molecular research laboratory, national biorepository and diagnostics laboratory, from 2007 to 2009. The CTR supported research initiatives throughout CHI's forty (40) Oncology centers. Dr. Cornblatt is a Johns Hopkins University School of Medicine graduate with a Ph.D. in Pharmacology and Molecular Sciences (2004) and a postdoctoral fellowship (2004 to 2006) from the Johns Hopkins Bloomberg School of Public Health, Environmental Health Sciences Division of Toxicology in the United States.
- David Ryan
David Ryan，拥有投资和公开市场方面的经验。在过去的20年里，他参与了将多个首次公开募股推向市场的工作。他曾在一级和二级融资中帮助为众多上市公司筹集股权和债务融资，他曾在上市公司董事会任职，担任过从总裁到董事的各种职务。Ryan先生为审计委员会成员，于2020年11月至2022年4月期间担任或曾经担任HydroGraph Clean Power Inc.（“HydroGraph”）董事；于2019年8月至2022年3月期间担任International Battery Metals Ltd.（“International Battery”）董事（曾于2018年8月至2019年4月期间担任International Battery董事）；于2017年3月至2020年5月期间担任GlobeX Data Ltd.董事；首席执行官自2017年1月起担任Scotch Creek Ventures Inc.（“Scotch Creek”）董事；自2017年10月至2023年10月担任Ovation Science Inc.（“Ovation”）董事；自2010年8月起担任InsuraGuest Technologies Inc.（“InsuraGuest”）董事；自2020年11月起担任Glenstar Ventures Corp.（“Glenstar”）首席执行官、总裁和董事，自2013年4月起担任公司秘书和董事，自2020年6月起担任公司投资者关系副总裁（此前曾于2013年4月至2020年6月担任公司总裁）。
David Ryan,has experience in investment and public markets. For the past 20 years, he has been part of bringing multiple initial public offerings to market. He has helped raise both equity and debt financings for numerous public companies in both primary and secondary financings, and he has served on the board of public companies and in various roles, from president to director. Mr. Ryan is a member of the Audit Committee and serves or has served as a director of HydroGraph Clean Power Inc. ("HydroGraph") from November 2020 to April 2022; a director of International Battery Metals Ltd. ("International Battery") from August 2019 to March 2022 (previously served as a director of International Battery from August 2018 to April 2019); a director of GlobeX Data Ltd. from March 2017 to May 2020; the Chief Executive Officer and a director of Scotch Creek Ventures Inc. ("Scotch Creek") since January 2017; a director of Ovation Science Inc. ("Ovation") from October 2017 to October 2023; a director of InsuraGuest Technologies Inc. ("InsuraGuest") since August 2010; the Chief Executive Officer, President and a director of Glenstar Ventures Corp. ("Glenstar") since November 2020, and the Secretary and a director of the Company since April 2013 and Vice-President, Investor Relations, of the Company since June 2020 (previously served as the President of the Company from April 2013 to June 2020).- David Ryan，拥有投资和公开市场方面的经验。在过去的20年里，他参与了将多个首次公开募股推向市场的工作。他曾在一级和二级融资中帮助为众多上市公司筹集股权和债务融资，他曾在上市公司董事会任职，担任过从总裁到董事的各种职务。Ryan先生为审计委员会成员，于2020年11月至2022年4月期间担任或曾经担任HydroGraph Clean Power Inc.（“HydroGraph”）董事；于2019年8月至2022年3月期间担任International Battery Metals Ltd.（“International Battery”）董事（曾于2018年8月至2019年4月期间担任International Battery董事）；于2017年3月至2020年5月期间担任GlobeX Data Ltd.董事；首席执行官自2017年1月起担任Scotch Creek Ventures Inc.（“Scotch Creek”）董事；自2017年10月至2023年10月担任Ovation Science Inc.（“Ovation”）董事；自2010年8月起担任InsuraGuest Technologies Inc.（“InsuraGuest”）董事；自2020年11月起担任Glenstar Ventures Corp.（“Glenstar”）首席执行官、总裁和董事，自2013年4月起担任公司秘书和董事，自2020年6月起担任公司投资者关系副总裁（此前曾于2013年4月至2020年6月担任公司总裁）。
- David Ryan,has experience in investment and public markets. For the past 20 years, he has been part of bringing multiple initial public offerings to market. He has helped raise both equity and debt financings for numerous public companies in both primary and secondary financings, and he has served on the board of public companies and in various roles, from president to director. Mr. Ryan is a member of the Audit Committee and serves or has served as a director of HydroGraph Clean Power Inc. ("HydroGraph") from November 2020 to April 2022; a director of International Battery Metals Ltd. ("International Battery") from August 2019 to March 2022 (previously served as a director of International Battery from August 2018 to April 2019); a director of GlobeX Data Ltd. from March 2017 to May 2020; the Chief Executive Officer and a director of Scotch Creek Ventures Inc. ("Scotch Creek") since January 2017; a director of Ovation Science Inc. ("Ovation") from October 2017 to October 2023; a director of InsuraGuest Technologies Inc. ("InsuraGuest") since August 2010; the Chief Executive Officer, President and a director of Glenstar Ventures Corp. ("Glenstar") since November 2020, and the Secretary and a director of the Company since April 2013 and Vice-President, Investor Relations, of the Company since June 2020 (previously served as the President of the Company from April 2013 to June 2020).
- Nedira Salzman Frenkel
Nedira Salzman Frenkel是一家以色列生物技术公司的业务发展副总裁，在那里她带头推动了BD努力，从而与一家全球顶级制药公司就3期临床开发达成了具有约束力的许可条款清单。在此之前，Salzman-Frenkel女士是Salzman集团的首席执行官，该集团是一家全球制药和合同研究组织（CRO），专注于新型小分子疗法的临床前和临床开发，同时为制药、医疗器械和农用化学品行业提供服务。萨尔茨曼-弗伦克尔女士在任职期间获得了这些行业约3000万美元的CRO合同。在此之前，Salzman-Frenkel女士共同创立了Beetlebung Pharma Ltd.和Solviva，并在Salzman Capital Ventures，Ltd.领导业务发展工作，该公司提供全方位服务的制药支持、定制实验室研发和药物开发咨询。
Nedira Salzman Frenkel,was Vice President of Business Development at an Israeli biotech, where she spearheaded BD efforts, resulting in a binding licensing term-sheet with a top global pharmaceutical company for Phase 3 clinical development. Prior to this, Ms. Salzman-Frenkel was CEO of the Salzman Group, a global pharmaceutical and contract research organization (CRO) that was focused on pre-clinical and clinical development of novel, small-molecule therapeutics, while providing services to the pharmaceutical, medical device, and agrochemical industries. During her tenure, Ms. Salzman-Frenkel secured approximately $30 million dollars in CRO contracts across these industries. Prior to this, Ms. Salzman-Frenkel co-founded Beetlebung Pharma Ltd. and Solviva, as well as led business development efforts at Salzman Capital Ventures, Ltd., a firm providing full-service pharmaceutical support, custom laboratory research and development, and drug development consultation.- Nedira Salzman Frenkel是一家以色列生物技术公司的业务发展副总裁，在那里她带头推动了BD努力，从而与一家全球顶级制药公司就3期临床开发达成了具有约束力的许可条款清单。在此之前，Salzman-Frenkel女士是Salzman集团的首席执行官，该集团是一家全球制药和合同研究组织（CRO），专注于新型小分子疗法的临床前和临床开发，同时为制药、医疗器械和农用化学品行业提供服务。萨尔茨曼-弗伦克尔女士在任职期间获得了这些行业约3000万美元的CRO合同。在此之前，Salzman-Frenkel女士共同创立了Beetlebung Pharma Ltd.和Solviva，并在Salzman Capital Ventures，Ltd.领导业务发展工作，该公司提供全方位服务的制药支持、定制实验室研发和药物开发咨询。
- Nedira Salzman Frenkel,was Vice President of Business Development at an Israeli biotech, where she spearheaded BD efforts, resulting in a binding licensing term-sheet with a top global pharmaceutical company for Phase 3 clinical development. Prior to this, Ms. Salzman-Frenkel was CEO of the Salzman Group, a global pharmaceutical and contract research organization (CRO) that was focused on pre-clinical and clinical development of novel, small-molecule therapeutics, while providing services to the pharmaceutical, medical device, and agrochemical industries. During her tenure, Ms. Salzman-Frenkel secured approximately $30 million dollars in CRO contracts across these industries. Prior to this, Ms. Salzman-Frenkel co-founded Beetlebung Pharma Ltd. and Solviva, as well as led business development efforts at Salzman Capital Ventures, Ltd., a firm providing full-service pharmaceutical support, custom laboratory research and development, and drug development consultation.